Table 1.
Demographic and clinical parameters
| LBBB group | Non-LBBB group | P value | |
|---|---|---|---|
| Age (years) | 61 ± 14 | 58 ± 16 | 0.676 |
| Gender (female:male) | 2:9 | 2:9 | – |
| Height (cm) | 173 ± 9 | 172 ± 7 | 0.763 |
| Weight (kg) | 88 ± 20 | 85 ± 11 | 0.688 |
| BSA (m2) | 2.0 ± 0.2 | 2.0 ± 0.2 | 0.728 |
| Heart rate (bpm) | 71 ± 13 | 68 ± 9 | 0.595 |
| BP systolic (mmHg) | 135 ± 15 | 132 ± 21 | 0.733 |
| BP diastolic (mmHg) | 76 ± 6 | 82 ± 17 | 0.357 |
| Etiology (ICM:NICM) | 4:7 | 4:7 | – |
| NYHA classification | 2 (1–3) | 2 (1–3) | 0.401 |
| QRS duration (ms) | 160 ± 20 | 106 ± 9 | < 0.001 |
| AV block I (number of patients) | 1 | 1 | – |
| LV diastolic function according to echo Doppler indices | |||
| Normal | 6 | 6 | – |
| Relaxation abnormality | 4 | 4 | – |
| Pseudonormal filling | 1 | 1 | – |
| Restrictive filling | 0 | 0 | – |
| MRI data | |||
| LVEF (%) | 34 ± 9 | 37 ± 9 | 0.550 |
| LVEDV (ml) | 261 ± 90 | 235 ± 72 | 0.462 |
| LVEDV-index (ml/m2) | 129 ± 48 | 116 ± 32 | 0.455 |
| LVESV (ml) | 177 ± 82 | 154 ± 69 | 0.490 |
| Medication (number of patients) | |||
| Beta-blocker | 11 | 8 | – |
| ACE-I or ARB | 11 | 9 | – |
| Calcium channel blocker | 2 | 0 | – |
| Nitrate (long lasting) | 0 | 1 | – |
| Antithrombotic/anticoagulant | 6 | 8 | – |
| Statin | 6 | 7 | – |
| Diuretics | 6 | 4 | – |
Mean ± SD, except for NYHA classification: median (range). ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, AV atrioventricular, BP blood pressure, bpm beats per minute, BSA body surface area, NICM nonischemic cardiomyopathy, EDV end-diastolic volume, ESV end-systolic volume, EF ejection fraction, ICM ischemic cardiomyopathy, LV left ventricle, NYHA New York Heart Association. The echo Doppler indices for LV diastolic function was applied according to standard recommendations [29]